Galectin-9

Galectin-9 Informations sur la molécule

Nom anglais	Galactoside-binding lectin Galectin 9	Nombre de médicaments commercialisés	0
Nombre de médicaments cliniques	2	Alias de la cible	Ecalectin，Tumor antigen HOM-HD-21，Galectin-9，Lectin， Galactoside-Binding， Soluble， 9，LGALS9
Phase de R&D la plus avancée	Phase 2 Clinical

Nom anglais	Galactoside-binding lectin Galectin 9
Alias de la cible	Ecalectin，Tumor antigen HOM-HD-21，Galectin-9，Lectin， Galactoside-Binding， Soluble， 9，LGALS9
Nombre de médicaments commercialisés	0
Nombre de médicaments cliniques	2
Phase de R&D la plus avancée	Phase 2 Clinical

Galectin-9 Liste de produits

Attribut
Protein (3)
Bibliothèque de produits
En ligne (3)
Espèces
Human (3)
Étiquette
His Tag (1)His Tag & Avi Tag (1)Tag Free (1)
Marqueur
Unconjugated (2)Biotin-labeled (1)

Numéro de produit	Espèces	Système d'expression	Description du produit	Pré-commande/Commande
LG9-H5213	Human	HEK293	Human Galectin-9 / LGALS9 Protein, Tag Free (MALS verified)	Ajouter au panier
LG9-H5244	Human	HEK293	Human Galectin-9 / LGALS9 Protein, His Tag, low endotoxin	Ajouter au panier
LG9-H82H3	Human	HEK293	Biotinylated Human Galectin-9 / LGALS9 Protein, His,Avitag™	Ajouter au panier

Quantité totale3

Demande de produit

Galectin-9Contexte de la molécule

Galectin-9 (LGALS9) is also known as tumor antigen HOM-HD-21 and ecalectin. Galectins are a family of proteins defined by their binding specificity for β-galactoside sugars, such as N-acetyllactosamine (Galβ1-3GlcNAc or Galβ1-4GlcNAc), which can be bound to proteins by either N-linked or O-linked glycosylation. As for Galectin-9, it has high affinity for the Forssman pentasaccharide, and it is also the ligand for HAVCR2/TIM3. Forthermore, Galectin-9 stimulates bactericidal activity in infected macrophages by causing macrophage activation and IL1B secretion which restricts intracellular bacterial growth.

Galectin-9Alias de la molécule

Galectin-9,LGALS9,Ecalectin

Informations sur les médicaments cliniques

Nom anglais	Code de recherche	Phase de R&D	Entreprise	Indication	Essai clinique
LYT-200	LYT-200	Phase 2 Clinical	Puretech Health	Carcinoma, Transitional Cell; Cholangiocarcinoma; Colorectal Neoplasms; Head and Neck Neoplasms; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Neoplasm Metastasis; Pancreatic Neoplasms; Solid tumours	Details
Anti-Gal9 antibody (Fibrogen)	FG-3165; HFB-200901; HFB-200902; HFB2009; HFB2009 series; HFB9-2	Phase 1 Clinical	HiFiBiO Therapeutics	Solid tumours	Details